8-K: Astria Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Astria Therapeutics reports financial results for Q4 and full year 2024, highlighting progress in clinical trials for Navenibart (STAR-0215) and STAR-0310.

Summary

• Astria Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is advancing its ALPHA-ORBIT pivotal Phase 3 trial evaluating Navenibart (STAR-0215) in hereditary angioedema (HAE) with both every 3-month and every 6-month administration.
• Initial efficacy and safety data from the Navenibart ALPHA-SOLAR long-term extension trial are expected in mid-2025.
• The Phase 1a trial of STAR-0310, a potential best-in-class monoclonal antibody OX40 antagonist, is ongoing with initial results anticipated in Q3 2025.
• Astria initiated the ALPHA-ORBIT pivotal Phase 3 trial of navenibart in February 2025, with top-line results expected in early 2027.
• The primary endpoint of the ALPHA-ORBIT trial is time-normalized monthly HAE attacks at 6 months.
• Final top-line results from the Phase 1b/2 ALPHA-STAR trial of navenibart, announced in December 2024, showed a 90-95% reduction in mean monthly attack rate and up to a 67% attack-free rate over 6 months.
• As of December 31, 2024, Astria had cash, cash equivalents, and short-term investments of $328.1 million.
• The company expects its cash to fund operations into mid-2027.
• Research and development expenses were $77.1 million for the full year 2024.
• General and administrative expenses were $34.5 million for the full year 2024.
• Net loss for the full year 2024 was $94.3 million, or $1.68 per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials and a strong cash position, although offset by the net loss.

Positives

• The ALPHA-ORBIT Phase 3 trial for Navenibart is underway, offering potential for less frequent dosing (every 3 or 6 months) for HAE patients.
• Positive final results from the ALPHA-STAR trial demonstrated significant reduction in HAE attack rates.
• The company has a strong cash position of $328.1 million, providing runway into mid-2027.
• The Phase 1a trial of STAR-0310 is progressing, with potential for a best-in-class OX40 antagonist for atopic dermatitis.

Negatives

• The company reported a net loss of $94.3 million for the full year 2024.
• Research and development expenses increased to $77.1 million for the full year 2024, reflecting increased investment in clinical trials.

Risks

• Clinical trial results may not be as favorable as anticipated.
• Regulatory approvals for Navenibart and STAR-0310 are not guaranteed.
• Competition in the HAE and atopic dermatitis markets could impact the commercial success of Astria's products.
• Unexpected cash expenditures could shorten the company's cash runway.

Future Outlook

Astria expects its current cash position to fund operations into mid-2027, including the completion of the ALPHA-ORBIT Phase 3 trial for Navenibart and the Phase 1a trial for STAR-0310.

Management Comments

• 2025 promises to be an exciting year for Astria, and we are building on the momentum from a successful 2024 with the initiation of two important clinical trials, said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
• We believe that navenibart has the potential to be the market-leading therapy for HAE, and we look forward to building on our track record of strong execution throughout the trial.

Industry Context

Astria is focusing on developing therapies for allergic and immunologic diseases, specifically targeting hereditary angioedema and atopic dermatitis, which are areas with significant unmet medical needs and growing market opportunities.

Comparison to Industry Standards

• Astria's navenibart is competing with existing HAE therapies like Takeda's Takhzyro and BioCryst's Orladeyo.
• The ALPHA-ORBIT trial's design, including both Q3M and Q6M dosing arms, aims to provide patient-centric dosing flexibility, potentially differentiating it from competitors.
• STAR-0310 is positioned as a potential best-in-class OX40 antagonist, competing with other companies developing therapies for atopic dermatitis, such as Sanofi and Regeneron with Dupixent.

Stakeholder Impact

• Positive impact on patients with HAE and atopic dermatitis if Navenibart and STAR-0310 are successfully developed and approved.
• Potential returns for shareholders if the company achieves its clinical and commercial goals.
• Continued employment and growth opportunities for employees.

Next Steps

• Continue enrollment and execution of the ALPHA-ORBIT Phase 3 trial for Navenibart.
• Release initial safety and efficacy data from the ALPHA-SOLAR long-term extension trial in mid-2025.
• Release early proof-of-concept results from the Phase 1a trial of STAR-0310 in Q3 2025.
• Advance Phase 3 development and testing of drug device combinations for potential dosing of navenibart.

Key Dates